MicroRNA (miRNA) is a small, non-coding RNA molecule which plays a role in the carcinogenesis and progression of cancers. Abnormal expression of miRNA in plasma has been found in some patients with malignant tumors.
Background
MicroRNA (miRNA) is a small, non-coding RNA molecule found in eukaryotes, containing about 22 nucleotides, which plays a negative role in transcriptional and post-transcriptional regulation of gene expression [1] . Some studies concluded that over 30% of the proteins in the human body are regulated by miRNA via several mechanisms [2] . This indicates miRNA may be important regulatory factors in many diseases. Recent research has shown that miRNAs not only regulate various biological processes, but are also associated with the carcinogenesis and progression of diverse human cancers [3] [4] [5] . MiRNA-30a, a member of the miR-30 family, located at human chromosome 6q13, has 2 mature forms: miR-30a-3p and miRNA-30a-5p [6] . Increasing evidence confirms the close relationship between miRNA-30a expression level and numerous types of human cancers [7, 8] , but the exact role of miRNA-30a in cancers remains controversial. Some research suggests that miRNA-30a may act as a tumor suppressor, but other studies suggest it acts as an oncogene.
Lung cancer, a common malignant lung tumor, has become the major cause of cancer-related death worldwide [9] . It is divided into 2 broad classes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for 80% of human lung cancer, and the 5-year survival rate is only 15%. Uncontrolled cell growth and multitudinous metastasis of lung cancer lead to high morbidity and mortality. Distinguishing the significant molecular alterations at the early stage of lung cancer contributes to early diagnosis, and thus to early treatment, which may have the potential to reduce the mortality of lung cancer. Currently, the diagnosis of lung cancer mainly depends on clinical symptoms, sputum cytology, immunological examinations, bronchoscopy, percutaneous needle lung biopsy, and many common tumor markers. Because lung cancer screening cannot normally be conducted in high-risk populations and in those lacking symptoms at the early stage, early diagnosis and timely treatment for lung cancer are still challenges for clinical practice.
Tumor markers are biomarkers found in various body fluids or body tissues, which can help detect the presence and development of tumors. Each tumor marker has a high diagnostic value in 1 or several specific tumor types, such as alpha fetoprotein (AFP) in hepatic carcinoma diagnosis. At present, the following tumor markers are used for lung cancer diagnosis and screening: cytokeratin 19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), progastrin-releasing peptide (ProGRP), carbohydrate antigen 125 (CA125), and carbohydrate Antigen 199 (CA199). Due to insufficient sensitivity and specificity of these common tumor markers [10, 11] , new biomarkers with a high diagnostic value for lung cancer diagnosis are needed.
MiRNA-30a may be used as a tumor biomarker in lung cancer diagnosis, as some researches [7, 8] found its expression was remarkably downregulated in lung cancer tissue. Because invasive examination or surgery must be performed to obtain the lung cancer tissue, it is almost impossible to use the miR-NA-30a in the lung tissue as a biomarker for clinical lung cancer screening. Furthermore, after invasive examination or surgery, precise diagnostic results will be provided by pathological examination, while the biomarker from the tissue is not necessary for cancer diagnosis. Therefore, tumor markers in plasma or sputum have the advantage of convenience compared with those in the lung tissue. This study aimed to investigate the expression pattern of miRNA-30a in the plasma of NSCLC patients, and also to evaluate the potential of plasma miRNA30a as a novel tumor biomarker in NSCLC diagnosis.
Material and methods

Patients
This study was approved by the Medical Ethics Committee of the West China Hospital, Sichuan University. Three patients with lung cancers who had undergone surgical resection in the Department of Thoracic Surgery at West China Hospital, Sichuan University, were included in array analysis. All the patients were males with a history of cigarette smoking. The average age was 59±5.57 years. All the tissues were confirmed as adenocarcinoma with TNM stage I and II. Tumor tissues and para-carcinoma normal tissues were collected after the resection of lung tissue. Samples were stored at -80°C until use.
A total of 99 plasma samples were collected from lung cancer patients who underwent surgical resection with histologically verified lung cancer in the Department of Thoracic Surgery at West China Hospital, Sichuan University between 2012 and 2014. The patients consisted of 68 males and 31 females and the mean age at surgery was 60.73±9.42 years. Pathological types included 52 cases of adenocarcinoma, 35 cases of squamous cell carcinoma (SCC), 6 cases of unclassified cancers, and the other 6 cases were small cell lung cancer (SCLC). According to the 7th Lung Cancer TNM Classification and Staging System, revised by the International Union Against Cancer (UICC) in 2009, intra-operative and postoperative pathology indicated 56 cases with stages I and II and 37 with stages III and IV cancer. Twenty patients (mean age 62.3±8.78, 11 males, 9 females) with benign lung nodules, such as tuberculosis, inflammatory pseudotumor, pulmonary cystitis and aspergillosis, verified by pathology, served as benign controls. Seventy-six healthy persons without obvious disease who had health examinations in our hospital were also included as healthy controls, with a mean age of 51.5±8.26 years. There were 47 males and 29 females in the healthy control group. All plasma samples of controls were collected during the same period.
Plasma specimen collection
To avoid the impacts of diet, physiological activities, and physical activities on the sample, all blood specimens were collected between 7 and 8 AM after fasting for at least 8 h. We collected 3-5 ml of venous blood into an EDTA-anticoagulant tube (BD, Franklin Lakes, NJ, USA), and processed by centrifugation at 2000 rpm for 8 min. Plasma was transferred to a fresh tube (Axygen Scientific, Union City, CA, USA) and stored at -80°C until use.
RNA extraction and reverse transcriptase
Total RNA was extracted from plasma using the Trizol reagent (Invitrogen, Carlsbad, CA, USA), and then the RNA pellet was dissolved in 30 ul of RNAase free water and stored at -80°C for use. The purity and concentration of RNA was determined by spectrophotometer. Reverse transcription was conducted with Thermo Scientific Revert Aid Reverse kit (Thermo, Waltham, MA, US) and cDNA was collected after the transcription. Total RNA of lung tissue was extracted using Trizol (Invitrogen) and RNeasy mini kit (QIAGEN) according to the manufacturer's instructions.
miRNA array
MiRCURY LNA™ microRNA Arrays (v.10.0, Exiqon) were used in array analysis. The samples were labeled using the miRCURY™ Hy3™/Hy5™ Power labeling kit (Exiqon) and hybridized on the miRCURY™ LNA Array (Exiqon). Scanning was performed with the Axon GenePix 4000B microarray scanner. GenePix pro software (V6.0) was used to read the raw intensity of the image. The intensity of the green signal was calculated after background subtraction and 4 replicated spots of each probe on the same slide were averaged. The Median Normalization Method was used to obtain Normalized Data and Normalized Data=(Foreground-Background)/median. Unsupervised hierarchical clustering and correlation analysis were performed on the miRNA expression profiling. The software produced the scatter plot and the corresponding correlation R-value.
Quantitative Real-Time PCR
Quantitative real-time PCR (qRT-PCR) was performed on the IQ5 Real-time PCR system (Bio-Rad, Hercules, CA, USA) under the following conditions: incubated at 95°C for 3 min followed by 40 cycles of 10 s at 95°C, 15 s at 59°C, and 72°C for 10 s. The relative transcript levels of miRNA-30a were calculated using the 2 -DCT method. U6-snRNA acted as an external control, and all primers were synthesized by RiboBio Co. (Guangzhou, China).
Statistical analysis
Data analyses were performed using SPSS version 19.0 (SPSS, Inc., Chicago, IL). The data are expressed as means±SEMs. ANOVA, Kruskal-Wallis Test, multiple linear regression analysis, and the unpaired t test were used to distinguish the differences between groups. P<0.05 was considered as a statistically significant difference with 2-tailed tests. ROC curve was used to analyze the diagnosis value, including AUC, cutoff point, sensitivity, and specificity.
Results
Array results
To investigate the different expression of miRNA in lung cancer tissues, the miRNA expression profile was analyzed with array in 3 lung adenocarcinoma patients. Six miRNAs were downregulated in tumor tissue compared with para-carcinoma normal tissues (Table 1 , p<0.05). No miRNA was found significantly upregulated in tumor tissue compared with para-carcinoma normal tissues. Correlation coefficient matrix analysis showed that most of the miRNA expression levels remained almost the same in tumor tissues compared with para-carcinoma normal tissues (Table 2 ). This was further demonstrated by the Heat Map and Unsupervised Hierarchical Clustering (Figure 1 ). 
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Plasma miRNA-30a in three groups
As miRNA-30a was one of the most downregulated miRNAs in our array data, we investigated the expression levels of miR-NA-30a in plasmas of NSCLC patients using qRT-PCR, compared with benign controls and healthy controls. To our surprise, the level of miRNA-30a was significantly increased in the NSCLC group compared to the benign and healthy control groups (P<0.01, Figure 2A ).
We found that there was a significant difference in age between the healthy controls and the other 2 groups (P<0.05) during the data analysis. To evaluate if the age impacted our result authenticity, we grouped the healthy controls to 3 age grades (30-50 years, 51-70 years, and >70 years) and further analyzed the data based on the age groups. As shown in Figure  2B , there is no significant difference in the plasma miRNA-30a between these 3 age groups ( Figure 2B ). We also compared plasma miRNA-30a level in the control included subjects who had the age matched to the patients group and higher plasma mrRNA-30a also found in lung cancer group (data not shown).
The relationship between miRNA-30a expression and histological types
All lung cancer patients except unclassified cases were divided into 3 groups according to histological type: lung adenocarcinoma, lung squamous cell cancer (SCC), and small cell lung cancer (SCLC). There were no significant differences in the plasma miRNA-30a levels among these 3 groups (Figure 3 ).
The correlation between plasma miRNA-30a and NSCLC clinicopathologic features
To investigate the possible relationships between plasma miR-NA-30a levels and NSCLC clinicopathologic features, we used multiple linear regression analysis to analyze the data based on the following factors: age, gender, smoking history, pathological type, TNM classification, lymph node metastasis, and distant metastasis (the assignment of independent variable is shown in Table 3 ). Then, as shown in Table 4 , no statistically significant correlation was found between miRNA-30a levels and these characteristics.
Diagnostic value analysis of miRNA-30a levels using Receiver Operating Characteristic curves (ROC curve)
Pathologic result, as the criterion standard for diagnosis, was used to evaluate the value of miRNA-30a level as the test variable in the diagnosis of NSCLC. ROC curve analysis showed that the Area Under the Curve (AUC) of ROC was 0.727, indicating the miRNA-30a level may be a valuable index in diagnosing NSCLC (Figure 4 ).
Diagnosis cut-off point
After analyzing the ROC curve of miRNA-30a expression, the top Youden index was selected as the cut-off point for NSCLC diagnosis [12] , depending on the sensitivities and specificities of different cut-off points. As indicated in Table 5 , the best diagnostic cut-off value of miRNA-30a levels in plasma stood at 0.061 (sensitivity and specificity were 61.0 and 84.3%, respectively).
The results based on inpatients only
The data above ( Figure 4 , Table 5 ) were calculated with both the benign control group and the healthy control group. In fact, tumor biomarker tests are applied not only to screening asymptomatic and high-risk populations, but also to differential diagnosis for lung cancer. Although there was no statistically significant difference in miRNA-30a expression levels between the healthy group and the benign group, we re-analyzed the data excluding the healthy group. The results may Table 2 . Correlation coefficient matrix analysis of miRNA expression in lung cancer tissues and para-carcinoma normal tissues. Most miRNA expression levels in tumor tissues remained the same compared with para-carcinoma normal tissues.
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be more useful for use in clinical practice. The best diagnostic cut-off value was 0.095 with 54.9% and 94.4% sensitivity and specificity, respectively ( Figure 5 , Table 6 ). 
Discussion
Although several new tumor biomarkers have been studied recently [13] , biomarkers from minor invasive procedures should be more useful in the screening and early diagnosis of lung cancer. In this study, we first investigated the expression profile of miRNA in lung cancer tissue with arrays. Array data suggested that miRNA-30a level was downregulated in lung cancer tissues compared with para-carcinoma normal tissue. Then, we measured this miRNA in the plasma. To our surprise, the average level of miRNA-30a was dramatically increased in plasma of NSCLC patients compared with both the benign control group and the healthy group (P<0.01). This suggests that miR-NA-30a may be used as a biomarker in NSCLC diagnosis. We are unsure whether the sample size influenced the difference of plasma miRNA-30a level between the benign and healthy groups (P>0.05). The average level of miRNA-30a in the benign group was higher than that in the healthy group, implying miRNA-30a may play a role in various pulmonary diseases. In addition, no significant correlation was found between the miRNA-30a level and NSCLC clinicopathologic features, including histological type, age, gender, smoking history, TNM classification, lymph node metastasis, distant metastasis, and clinical stage.
Baffa et al. [14] found that subtypes of the miRNA-30 family (miRNA-30a, 30d, and 30e) were remarkably downregulated in metastatic cancerous tissues, and similar results were reported in the following tumor tissues: kidney [15] , lung [16, 17] , leukemia [18] , and breast [19] . Furthermore, miRNA-30a was a markedly and frequently decreased miRNA compared to other members of the miRNA-30 family [14, 20, 21] . Those phenomena imply that miRNA-30a may restrain the generation and progress of tumors. At present, most authors consider miRNA-30a as a tumor suppressor, inhibiting the malignant phenotype of tumors [8, 18, 20, 21] , including lung cancer.
Although the mechanism of miRNA-30a as a tumor suppressor in lung cancer is still not entirely clear, 2 possibilities have been suggested. Wu et al. [22] found that the miRNA-30 family negatively regulates the expression of Ubc9 (Ubiquitin Conjugating Enzyme), the sole E2-conjugating enzyme for SUMOylation, which has been proven to possess an oncogenic function, and then inhibit its carcinogenesis in lung cancer. Kumarswamy et al. [8] found miRNA-30a targets the 3'-UTR of Snai1 and reduces its expression, up-regulates the E-cadherin (epithelial marker) expression, and correlates positively with N-cadherin (mesenchymal marker) expression, resulting in a decrease of the EMT (epithelial to mesenchymal transition), finally inhibiting invasion and metastasis of NSCLC. Due to its function of carcinostasis, the decrease of miRNA-30a may lead to tumorigenesis in NSCLC. Thus, significantly downregulated miRNA30a in cancer tissues compared with para-carcinoma normal tissue may promote NSCLC.
In addition to the mechanisms described above, unknown mechanisms may affect the interaction between NSCLC and miR-NA-30a. In this study we measured the plasma miRNA-30a in 3 different groups (NSCLC group, benign control, and healthy control). Unexpectedly, we found plasma miRNA-30a expression level increased significantly in NSCLC patients compared with benign and healthy controls (P<0.01). This suggests to us that miRNA-30a may be involved in NSCLC via unknown mechanisms outside the lung. It is possible that NSCLC follows the abnormal downregulation of miRNA-30a in lung tissue, leading to the increase of miRNA-30a in plasma to restrain the metastasis of existing lung cancer in some way. The role of increased plasma miRNA-30a in NSCLC needs to be investigated further.
Further analysis was performed to evaluate the diagnostic value of miRNA-30a via ROC curve [23] . According to the clinical requirements, we analyzed the data with the following 2 conditions: including and excluding the healthy group. The AUC of ROC in the 2 conditions was similar, at about 72.2%, which Table 6 . Diagnosis cut-off point for NSCLC base on in-patients only.
Cut-off -cut-off point; TPR -true positive rate (sensitivity); TNR -true negative rate (specificity); LR+ -positive likelihood ratio; LR--negative likelihood ratio; YI -Youden index. Table 5 . Diagnosis cut-off point for NSCLC.
Cut-off -cut-off point; TPR -true positive rate (sensitivity); TNR -true negative rate (specificity); LR+ -positive likelihood ratio; LR--negative likelihood ratio; YI -Youden index.
653 shows miRNA-30a expression level has a moderate accuracy in NSCLC diagnosis. We then compared the cut-off value-related data for the 2 conditions, and a high specificity (94.4%) was observed in the inpatient group, indicating miRNA-30a testing may be a potential candidate in lung cancer differential diagnosis for inpatients. Many studies [24] [25] [26] [27] [28] [29] [30] [31] have revealed a positive correlation between levels of the most common tumor markers (such as CEA, CYFRA21-1, NSE, and SCC) and clinical stage of NSCLC patients. These may indicate falsenegative results in early diagnosis, causing insufficient detection or diagnosis at an early stage. On the contrary, plasma miRNA-30a expression has a higher stability and less interference compared with traditional tumor markers, because no significant difference was found in patients with different clinical and pathological characteristics. This implies miRNA-30a may be helpful for preliminary NSCLC screening. As Figure 3 shows, trends in mean plasma miRNA-30a expression in the 3 lung cancer pathological types were different (adenocarcinoma >SCC>SCLC), although no statistically significant difference was found among the 3 types of pathology in our study. It is difficult to completely rule out the influence of sample size on this result. Further study should be conducted to investigate
